Sensation seeking has long been linked to risky behaviors in teens, but its role in eating-disorder psychopathology has been mixed. A 2026 study by Bogner and colleagues clarifies the picture in 400 German adolescents: sensation seeking matters for disordered eating, but the effects are moderated by weight status and emotional symptoms.1 Research Highlights Sensation seeking …
Binge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the only drug approved for moderate to severe BED, is showing promise not just in reducing episodes but also in altering brain function in ways previously not fully understood. Through a groundbreaking study, researchers …
As of February 2015, the FDA approved the psychostimulant Vyvanse (Lisdexamfetamine) for the treatment of binge eating disorder. In recent years, the popularity of Vyvanse has skyrocketed as an ADHD medication, as well as among those seeking to use it for ulterior purposes such as weight loss, academics, and sports performance. Many consider the medication …